Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report

Focal segmental glomerulosclerosis is a histopathological condition characterized by podocyte injury, which manifests as persistent proteinuria and progressive decline in renal function. It is classified into primary and secondary forms, with secondary focal segmental glomerulosclerosis often result...

Full description

Saved in:
Bibliographic Details
Main Authors: Sohrab Kharabaf, Matthew Nguyen, Dao Le, Ramy Hanna
Format: Article
Language:English
Published: SAGE Publishing 2025-07-01
Series:SAGE Open Medical Case Reports
Online Access:https://doi.org/10.1177/2050313X251353726
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839623680462684160
author Sohrab Kharabaf
Matthew Nguyen
Dao Le
Ramy Hanna
author_facet Sohrab Kharabaf
Matthew Nguyen
Dao Le
Ramy Hanna
author_sort Sohrab Kharabaf
collection DOAJ
description Focal segmental glomerulosclerosis is a histopathological condition characterized by podocyte injury, which manifests as persistent proteinuria and progressive decline in renal function. It is classified into primary and secondary forms, with secondary focal segmental glomerulosclerosis often resulting from factors such as obesity, hypertension, or genetic mutations. The management of secondary focal segmental glomerulosclerosis remains challenging due to the lack of standardized therapeutic guidelines. This case report describes a 21-year-old male diagnosed with biopsy-proven secondary focal segmental glomerulosclerosis, likely due to obesity-related hyperfiltration, who exhibited significant improvement in proteinuria following cyclosporine therapy. Despite initial treatment with renin–angiotensin system inhibitors and prednisone, the patient continued to have persistent proteinuria. Low-dose cyclosporine therapy was introduced, leading to a marked reduction in proteinuria without deterioration in renal function. This case highlights the potential role of cyclosporine in the management of secondary focal segmental glomerulosclerosis, particularly in cases with suspected genetic predisposition. Further research is needed to determine the long-term efficacy and safety of cyclosporine in secondary focal segmental glomerulosclerosis management.
format Article
id doaj-art-6fcffd72a4ea49ff9f9967b6c98a3d0b
institution Matheson Library
issn 2050-313X
language English
publishDate 2025-07-01
publisher SAGE Publishing
record_format Article
series SAGE Open Medical Case Reports
spelling doaj-art-6fcffd72a4ea49ff9f9967b6c98a3d0b2025-07-19T09:03:27ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2025-07-011310.1177/2050313X251353726Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case reportSohrab Kharabaf0Matthew Nguyen1Dao Le2Ramy Hanna3School of Medicine, University of California, Irvine, CA, USASchool of Medicine, University of California, Irvine, CA, USADivision of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, University of California, Irvine, CA, USADivision of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, University of California, Irvine, CA, USAFocal segmental glomerulosclerosis is a histopathological condition characterized by podocyte injury, which manifests as persistent proteinuria and progressive decline in renal function. It is classified into primary and secondary forms, with secondary focal segmental glomerulosclerosis often resulting from factors such as obesity, hypertension, or genetic mutations. The management of secondary focal segmental glomerulosclerosis remains challenging due to the lack of standardized therapeutic guidelines. This case report describes a 21-year-old male diagnosed with biopsy-proven secondary focal segmental glomerulosclerosis, likely due to obesity-related hyperfiltration, who exhibited significant improvement in proteinuria following cyclosporine therapy. Despite initial treatment with renin–angiotensin system inhibitors and prednisone, the patient continued to have persistent proteinuria. Low-dose cyclosporine therapy was introduced, leading to a marked reduction in proteinuria without deterioration in renal function. This case highlights the potential role of cyclosporine in the management of secondary focal segmental glomerulosclerosis, particularly in cases with suspected genetic predisposition. Further research is needed to determine the long-term efficacy and safety of cyclosporine in secondary focal segmental glomerulosclerosis management.https://doi.org/10.1177/2050313X251353726
spellingShingle Sohrab Kharabaf
Matthew Nguyen
Dao Le
Ramy Hanna
Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report
SAGE Open Medical Case Reports
title Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report
title_full Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report
title_fullStr Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report
title_full_unstemmed Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report
title_short Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report
title_sort controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine a case report
url https://doi.org/10.1177/2050313X251353726
work_keys_str_mv AT sohrabkharabaf controllingproteinuriainsecondaryfocalsegmentalglomerulosclerosiswithcyclosporineacasereport
AT matthewnguyen controllingproteinuriainsecondaryfocalsegmentalglomerulosclerosiswithcyclosporineacasereport
AT daole controllingproteinuriainsecondaryfocalsegmentalglomerulosclerosiswithcyclosporineacasereport
AT ramyhanna controllingproteinuriainsecondaryfocalsegmentalglomerulosclerosiswithcyclosporineacasereport